Covered recipient · General Payments record
JOSHUA S JACOBS
Allopathic & Osteopathic Physicians Allergy & Immunology Allergy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$314,248.30
453 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $220,120.17 | 74 |
| Consulting Fee | $50,302.50 | 13 |
| Travel and Lodging | $28,897.93 | 114 |
| Food and Beverage | $10,786.20 | 248 |
| Honoraria | $4,120.00 | 2 |
| Education | $21.50 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Shire North American Group Inc | $102,259.77 | 88 |
| Teva Pharmaceuticals USA, Inc. | $88,742.40 | 108 |
| AstraZeneca Pharmaceuticals LP | $38,235.22 | 56 |
| Regeneron Healthcare Solutions, Inc. | $31,098.13 | 54 |
| GENZYME CORPORATION | $24,148.98 | 37 |
| Regeneron Pharmaceuticals, Inc. | $10,415.39 | 11 |
| GlaxoSmithKline, LLC. | $6,668.01 | 27 |
| Fresenius Kabi USA, LLC | $5,647.59 | 6 |
| BioCryst Pharmaceuticals, Inc. | $3,197.65 | 6 |
| CSL Behring | $2,042.43 | 10 |
| Octapharma USA, Inc. | $585.10 | 4 |
| Novartis Pharmaceuticals Corporation | $231.52 | 11 |
| ALK-Abello, Inc | $191.04 | 9 |
| Pharming Healthcare, Inc. | $156.48 | 3 |
| Genentech, Inc. | $124.87 | 1 |
| Kaleo, Inc. | $107.34 | 7 |
| SANOFI-AVENTIS U.S. LLC | $99.85 | 1 |
| Covis Pharma B.V. | $65.84 | 3 |
| Genentech USA, Inc. | $53.79 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $50.87 | 3 |
| Circassia Pharmaceuticals Inc | $38.87 | 1 |
| OptiNose US, Inc. | $33.68 | 2 |
| PFIZER INC. | $33.10 | 2 |
| QOL Medical, LLC | $20.38 | 1 |
Page 7 of 10; records 301–350 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOSHUA S JACOBS
NPI 1215920673 · CMS profile ID 54402
Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy
WALNUT CREEK, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 7 of 10; records 301–350 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=7#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOSHUA S JACOBS, NPI 1215920673, CMS profile ID 54402. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 10; records 301–350 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JOSHUA S JACOBS, NPI 1215920673, CMS profile ID 54402. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 10; records 301–350 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JOSHUA S JACOBS, NPI 1215920673, CMS profile ID 54402, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 10; records 301–350 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=7#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
453 matching records · $314,248.30 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 301–350 of 453.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $6.00 | 05/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673398383 | CMS |
| Shire North American Group Inc | $62.45 | 05/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846163 | CMS |
| Shire North American Group Inc | $48.03 | 05/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846165 | CMS |
| Shire North American Group Inc | $481.95 | 05/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846167 | CMS |
| Shire North American Group Inc | $50.00 | 05/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846169 | CMS |
| Shire North American Group Inc | $19.20 | 05/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846171 | CMS |
| Shire North American Group Inc | $24.02 | 05/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846173 | CMS |
| Shire North American Group Inc | $4,125.00 | 05/03/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846155 | CMS |
| Shire North American Group Inc | $140.00 | 05/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846157 | CMS |
| Shire North American Group Inc | $153.90 | 05/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846159 | CMS |
| Shire North American Group Inc | $58.19 | 05/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846161 | CMS |
| Teva Pharmaceuticals USA, Inc. | $3,030.00 | 05/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697863441 | CMS |
| AstraZeneca Pharmaceuticals LP | $35.20 | 05/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685288977 | CMS |
| AstraZeneca Pharmaceuticals LP | $114.99 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685700387 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.43 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700178385 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,670.00 | 04/29/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673398375 | CMS |
| GlaxoSmithKline, LLC. | $96.57 | 04/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671140103 | CMS |
| Shire North American Group Inc | $4,125.00 | 04/26/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846153 | CMS |
| GENZYME CORPORATION | $1,580.00 | 04/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013745 | CMS |
| GENZYME CORPORATION | $9.16 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013747 | CMS |
| GENZYME CORPORATION | $3,686.00 | 04/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013749 | CMS |
| GENZYME CORPORATION | $258.00 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013857 | CMS |
| GENZYME CORPORATION | $13.95 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013859 | CMS |
| GENZYME CORPORATION | $124.07 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013861 | CMS |
| GENZYME CORPORATION | $22.45 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013863 | CMS |
| GENZYME CORPORATION | $36.00 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694013865 | CMS |
| GENZYME CORPORATION | $341.52 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694050483 | CMS |
| GENZYME CORPORATION | $473.43 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694283721 | CMS |
| Regeneron Healthcare Solutions, Inc. | $126.63 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673398373 | CMS |
| Teva Pharmaceuticals USA, Inc. | $11.65 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697851123 | CMS |
| Teva Pharmaceuticals USA, Inc. | $78.00 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697851125 | CMS |
| Teva Pharmaceuticals USA, Inc. | $44.08 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697851127 | CMS |
| Regeneron Healthcare Solutions, Inc. | $10.64 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673398371 | CMS |
| Shire North American Group Inc | $5,625.00 | 04/23/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846151 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,350.00 | 04/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685296901 | CMS |
| Kaleo, Inc. | $16.86 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693185741 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,560.00 | 04/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673398369 | CMS |
| Teva Pharmaceuticals USA, Inc. | $109.40 | 04/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697863489 | CMS |
| Teva Pharmaceuticals USA, Inc. | $105.69 | 04/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697863495 | CMS |
| Teva Pharmaceuticals USA, Inc. | $3,030.00 | 04/19/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697863419 | CMS |
| Teva Pharmaceuticals USA, Inc. | $6.70 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697700365 | CMS |
| GlaxoSmithKline, LLC. | $9.51 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670924549 | CMS |
| Shire North American Group Inc | $16.76 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846149 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.58 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697847255 | CMS |
| Shire North American Group Inc | $1,100.00 | 04/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846147 | CMS |
| Shire North American Group Inc | $4,125.00 | 04/12/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637846145 | CMS |
| Teva Pharmaceuticals USA, Inc. | $352.15 | 04/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697863449 | CMS |
| Pharming Healthcare, Inc. | $12.12 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694341455 | CMS |
| GlaxoSmithKline, LLC. | $15.68 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670339042 | CMS |
| Regeneron Healthcare Solutions, Inc. | $57.14 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673398361 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $385,852.83 | 52 |
| PY2024 | Recipient | $4,500.00 | 1 |
| PY2024 | Principal investigator | $448,685.78 | 51 |
| PY2023 | Recipient | $12,257.82 | 18 |
| PY2023 | Principal investigator | $532,990.69 | 118 |
| PY2022 | Principal investigator | $617,668.37 | 129 |
| PY2021 | Recipient | $6,631.04 | 2 |
| PY2021 | Principal investigator | $794,953.96 | 186 |
| PY2020 | Recipient | $600.56 | 2 |
| PY2020 | Principal investigator | $362,418.42 | 76 |
| PY2019 | Principal investigator | $452,657.15 | 128 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
52 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $10,699.09 | 12/11/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246791464 |
| Principal investigator 1 | CSL Behring | $1,974.00 | 11/17/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673452 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 11/07/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244049323 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 10/28/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192143445 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,589.80 | 10/23/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190310454 |
| Principal investigator 1 | CSL Behring | $2,465.00 | 10/22/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673450 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 10/22/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244049321 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,643.30 | 10/16/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223287035 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,376.59 | 10/08/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190306383 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 10/03/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244049319 |
| Principal investigator 1 | CSL Behring | $1,974.00 | 08/18/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673448 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,854.06 | 08/14/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190310456 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $30,521.64 | 08/08/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246786373 |
| Principal investigator 1 | CSL Behring | $171.24 | 07/31/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673384 |
| Principal investigator 1 | CSL Behring | $174.00 | 07/30/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673382 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,189.70 | 07/22/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223282916 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,143.80 | 07/22/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223282918 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,189.70 | 07/17/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223282784 |
| Principal investigator 1 | CSL Behring | $9,870.00 | 07/14/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673440 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,611.63 | 07/09/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT | No dispute reported | 06/30/2026 | 1185552291 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,332.00 | 07/01/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190310452 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,804.40 | 06/24/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281754 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,804.40 | 06/19/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281632 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,500.00 | 06/12/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281134 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,520.00 | 06/12/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281142 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,208.00 | 06/12/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223281146 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 06/06/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244049317 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,601.00 | 06/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223280764 |
| Principal investigator 1 | PFIZER INC. | $11,750.00 | 06/04/2025 | Non-covered Recipient Entity Allergy Asthma Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228790236 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 06/01/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223280518 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 06/01/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223280520 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,601.00 | 05/22/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223280114 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,202.00 | 05/15/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223279800 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $175.00 | 05/01/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223278728 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $179.90 | 04/29/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244049315 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,527.90 | 04/22/2025 | Non-covered Recipient Entity ALLERGY ASTHMA CLINICAL RESEARCH | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190299759 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,202.00 | 04/17/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223278184 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,750.00 | 04/11/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185552293 |
| Principal investigator 1 | CSL Behring | $76.00 | 04/11/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673422 |
| Principal investigator 1 | CSL Behring | $377.22 | 04/09/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673380 |
| Principal investigator 1 | CSL Behring | $118.24 | 04/07/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673378 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $17.65 | 03/26/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045444 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $21.41 | 03/26/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045446 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $72.80 | 03/26/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045448 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,353.30 | 03/20/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223276879 |
| Principal investigator 1 | CSL Behring | $85,432.20 | 03/18/2025 | Non-covered Recipient Entity Allergy And Asthma Clinical Research | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673454 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,151.30 | 02/20/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223275419 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $65,178.44 | 01/30/2025 | Non-covered Recipient Entity ALLERGY ASTHMA CLINICAL RESEARCH | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190299755 |
| Principal investigator 1 | Amgen Inc. | $17,616.56 | 01/27/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1246638957 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,478.32 | 01/24/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA CLINICAL RESEARCH INC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185552297 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,514.93 | 01/01/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH INCORPORATION | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190302401 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $225.39 | 01/01/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA CLINICAL RESEARCH INCORPORATION | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190302403 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $4,891.07 | 1 |
| PY2025 | Value of interest | $4,891.07 | 1 |
| PY2024 | Amount invested | $4,891.07 | 1 |
| PY2024 | Value of interest | $4,891.07 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
2 records · PY2024–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | Consortium of Independent Immunology Clinics, LLC | $4,891.07 | $4,891.07 | n/a | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1224798458 |
| PY2024 | Consortium of Independent Immunology Clinics, LLC | $4,891.07 | $4,891.07 | n/a | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1147099050 |